Table 1.
Characteristics of clinical and pathological data between subxiphoid approach and trans-sternal approach groups.
| Clinical characterstics | Subxiphoid group | Trans-sternal group | P |
|---|---|---|---|
| Gender, n | 0.519 | ||
| Male | 28 | 25 | |
| Female | 16 | 20 | |
| Age (years), median (range) | 49.1 (18–70) | 48.4 (25–76) | 0.785 |
| MGFA classification, n | 0.937 | ||
| I | 2 | 2 | |
| IIA | 4 | 6 | |
| IIB | 20 | 20 | |
| III | 18 | 17 | |
| WHO histologic type, n | 0.784 | ||
| A/AB | 7 | 9 | |
| B1/B2/B3 | 37 | 36 | |
| Maximal tumor size, mean (cm) | 2.9 ± 0.7 | 3.1 ± 0.7 | 0.162 |
| Masaoka–Koga stage, n | 0.714 | ||
| I | 41 | 40 | |
| II | 3 | 5 | |
| Bleeding, mean (ml) | 29.2 ± 10.7 | 151.1 ± 39.2 | <0.001 |
| Postoperative pain [0–10 (VAS score)] | |||
| 24 h postoperatively | 4.1 ± 1.1 | 6.5 ± 0.8 | <0.001 |
| 72 h postoperatively | 2.1 ± 0.7 | 3.7 ± 1.0 | <0.001 |
MGFA, Myasthenia Gravis Foundation of America.